NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT06245356 2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2 Recruiting
NCT06589830 2025-05-15
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Suzhou Teligene Ltd.
Phase 2 Not yet recruiting
NCT03043313 2024-11-26
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
Seagen Inc.
Phase 2 Completed
NCT05356897 2024-09-19
Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting
NCT03457896 2022-03-31
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
NSABP Foundation Inc
Phase 2 Unknown
NCT05193292 2022-01-14
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT04380012 2021-07-15
A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT03185988 2019-07-19
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
Peking University
Phase 2 Unknown
NCT03225937 2018-10-30
HERACLES
Fondazione del Piemonte per l'Oncologia
Phase 2 Unknown
NCT00006015 2013-05-03
Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00003995 2013-02-08
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2
National Cancer Institute (NCI)
Phase 2 Completed